223 related articles for article (PubMed ID: 34676950)
1. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
Adamec I; Jovanović I; Krbot Skorić M; Habek M
Eur J Neurol; 2022 Mar; 29(3):901-904. PubMed ID: 34676950
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
5. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Sellner J; Rommer PS
Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
[TBL] [Abstract][Full Text] [Related]
6. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
7. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
8. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
9. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
11. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
13. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G
Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
[TBL] [Abstract][Full Text] [Related]
14. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Edan G; Le Page E
Drugs; 2023 Oct; 83(15):1351-1363. PubMed ID: 37725259
[TBL] [Abstract][Full Text] [Related]
15. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.
von Essen MR; Chow HH; Holm Hansen R; Buhelt S; Sellebjerg F
Front Immunol; 2023; 14():1249201. PubMed ID: 37744364
[TBL] [Abstract][Full Text] [Related]
16. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S; Ponzano M; Ivaldi F; Signori A; Lapucci C; Casella V; Ferrò MT; Vigo T; Inglese M; Mancardi GL; Uccelli A; Laroni A
CNS Drugs; 2022 Jan; 36(1):83-96. PubMed ID: 34894339
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
Alonso R; Casas M; Lazaro L; Liguori NF; Pita C; Cohen L; Rojas JI; Pappolla A; Patrucco L; Cristiano E; Burgos M; Vrech C; Piedrabuena R; Pablo L; Deri N; Luetic G; Miguez J; Cabrera M; Martinez A; Zanga G; Tkachuk V; Tizio S; Carnero Contentti E; Knorre E; Leguizamon F; Mainella C; Nofal P; Liwacki S; Hryb J; Menichini M; Pestchanker C; Garcea O; Silva B
Mult Scler Relat Disord; 2023 Nov; 79():104935. PubMed ID: 37634468
[TBL] [Abstract][Full Text] [Related]
18. Pulsed immune reconstitution therapy in multiple sclerosis.
Sorensen PS; Sellebjerg F
Ther Adv Neurol Disord; 2019; 12():1756286419836913. PubMed ID: 30944586
[TBL] [Abstract][Full Text] [Related]
19. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
20. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
Kvistad SAS; Burman J; Lehmann AK; Tolf A; Zjukovskaja C; Melve GK; Bø L; Torkildsen Ø
J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):844-848. PubMed ID: 35508373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]